SAN ANTONIO CENTER OF BIOMARKERS OF RISK FOR PROSTATE CANCER (SABOR)

圣安东尼奥前列腺癌风险生物标志物中心 (SABOR)

基本信息

批准号：
7718746
负责人：
IAN M. THOMPSON
金额：
$ 5.25万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-04-01 至 2008-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7718746
关键词：
Affect African American Algorithms Androgen Receptor Behavioral Biological Markers Body mass index CAG repeat Caring Characteristics Clinical Clinical Data Cohort Studies Computer Retrieval of Information on Scientific Projects Database Constitutional Data Diet Digital Rectal Examination Discrimination Early Detection Research Network Early Diagnosis Energy Intake Enrollment Ethnic group Family history of Fatty acid glycerol esters Funding Genetic Variation Grant Hispanics Human Resources Institution Intake Leadership Length Malignant Neoplasms Malignant neoplasm of prostate Methylation Micronutrients Numbers Outcome PSA level Performance Population Positioning Attribute Prostate Cancer Prevention Trial Race Research Research Personnel Resources Risk Risk Factors SRD5A2 gene Semaphorins Sensitivity and Specificity Source Standards of Weights and Measures Testosterone 5-alpha-Reductase Underrepresented Minority United States United States National Institutes of Health Variant Vitamin D3 Receptor base cancer risk cohort design fruits and vegetables improved men validation studies

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Prostate cancer is the most common cancer in U.S. men. Existing biomarkers - digital rectal examination (DRE) and PSA - have poor sensitivity and specificity. Data from the Prostate Cancer Prevention Trial and other studies suggest that a combination of factors - constitutional (e.g., family history, genetic variations), behavioral (e.g., body mass index, diet), as well as somatic (e.g., GSTPi methylation) - can improve the discrimination between men with and without prostate cancer. The San Antonio Center for Biomarkers of Risk of Prostate Cancer (SABOR) is a population-based, minority and underserved-enriched, cohort study that collects extensive clinical data and biospecimens while tracking cancer-related outcomes, designed to discover, develop, and validate biomarkers of prostate cancer risk. To date, 3,142 men have been enrolled over approximately 3 years of accrual including 51% Hispanic or African American subjects. Using the entire EDRN CEVC efforts of SABOR, we have found several factors that affect prostate cancer risk including a number of genetic variations (CAG repeat length in the androgen receptor, Semaphorins 3B and 3F, SRD5A2, and variations of the Vitamin D receptor) and body mass index (higher values associated with lower levels of PSA). We have also found substantial differences in risk factors for prostate cancer in different ethnic groups (caloric intake, fat intake, micronutrient intake, body mass index, fruit and vegetable intake) as well as different performance characteristics of PSA and DRE in these ethnic/racial groups. In the SABOR renewal, we will complete recruitment of 9,000 men in the cohort, explore further these behavioral, constitutional, and somatic risk factors, develop and validate a multivariable prostate cancer risk algorithm, and conduct EDRN Network validation studies. The SABOR scientific personnel will continue to serve in their leadership positions within the Network, assisting the EDRN with the design, conduct, and analysis of early detection validation studies that will alter the standard of care of clinical practice in the United States.

该子项目是利用该技术的众多研究子项目之一资源由 NIH/NCRR 资助的中心拨款提供。子项目及研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金，因此可以在其他 CRISP 条目中表示。列出的机构是对于中心来说，它不一定是研究者的机构。前列腺癌是美国男性最常见的癌症。现有的生物标志物——直肠指检 (DRE) 和 PSA——敏感性和特异性较差。前列腺癌预防试验和其他研究的数据表明，多种因素的组合——体质（例如家族史、遗传变异）、行为（例如体重指数、饮食）以及躯体（例如 GSTPi 甲基化）——可以改善患有和未患有前列腺癌的男性之间的区别。圣安东尼奥前列腺癌风险生物标志物中心 (SABOR) 是一项以人群为基础、少数群体且服务水平低下的队列研究，收集广泛的临床数据和生物样本，同时跟踪癌症相关结果，旨在发现、开发和验证前列腺癌风险的生物标志物。迄今为止，在大约 3 年的累积过程中，已有 3,142 名男性入组，其中 51% 是西班牙裔或非裔美国人。通过 SABOR 的整个 EDRN CEVC 工作，我们发现了影响前列腺癌风险的几个因素，包括许多遗传变异（雄激素受体中的 CAG 重复长度、信号蛋白 3B 和 3F、SRD5A2 以及维生素 D 受体的变异）和体重指数（较高的值与较低的 PSA 水平相关）。我们还发现，不同种族的前列腺癌危险因素（热量摄入、脂肪摄入、微量营养素摄入、体重指数、水果和蔬菜摄入量）存在显着差异，而且这些种族/种族的 PSA 和 DRE 表现特征也存在差异。组。在 SABOR 更新中，我们将完成队列中 9,000 名男性的招募，进一步探索这些行为、体质和躯体风险因素，开发和验证多变量前列腺癌风险算法，并进行 EDRN 网络验证研究。 SABOR 科学人员将继续担任网络内的领导职务，协助 EDRN 设计、进行和分析早期检测验证研究，这些研究将改变美国临床实践的护理标准。